(Q43910370)

28 November 2017

title

Phase II study of weekly docetaxel in patients with metastatic breast cancer (English)

1 reference

28 November 2017

main subject

metastatic breast cancer

1 reference

1 reference

T Aihara

1

1 reference

28 November 2017

Y Kim

series ordinal

2

1 reference

28 November 2017

Y Takatsuka

series ordinal

3

1 reference

28 November 2017

publication date

1 February 2002

1 reference

28 November 2017

1 reference

28 November 2017

volume

13

1 reference

28 November 2017

issue

2

1 reference

28 November 2017

page(s)

286-292

1 reference

Docetaxel in patients with metastatic breast cancer: a phase II study of the National Cancer Institute of Canada-Clinical Trials Group

28 November 2017

cites work

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDF027

A multicentre phase II study of docetaxel 75 mg m-2 as first-line chemotherapy for patients with advanced breast cancer: report of the Clinical Screening Group of the EORTC. European Organization for Research and Treatment of Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDF027

Phase II trial of docetaxel in advanced anthracycline-resistant or anthracenedione-resistant breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDF027

Phase II trial of docetaxel: a new, highly effective antineoplastic agent in the management of patients with anthracycline-resistant metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDF027

A late phase II study of RP56976 (docetaxel) in patients with advanced or recurrent breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDF027

Docetaxel in the community setting: an analysis of 377 breast cancer patients treated with docetaxel (Taxotere) in the UK. UK Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDF027

Factors predicting for efficacy and safety of docetaxel in a compassionate-use cohort of 825 heavily pretreated advanced breast cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDF027

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDF027

Early clinical studies with docetaxel. Docetaxel Investigators Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDF027

Dose-dense therapy with weekly 1-hour paclitaxel infusions in the treatment of metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDF027

Phase I trial of docetaxel administered by weekly infusion in patients with advanced refractory cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDF027

Front-line treatment of metastatic breast cancer with docetaxel and epirubicin: a multicenter dose-escalation study. The Greek Breast Cancer Cooperative Group (GBCCG).

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDF027

21 January 2018

Identifiers

DOI

10.1093/ANNONC/MDF027

1 reference

28 November 2017

1 reference